Targeted immunotherapy: harnessing the immune system to battle multiple myeloma

被引:13
作者
Xu, Limei [1 ]
Wen, Caining [2 ]
Xia, Jiang [3 ]
Zhang, Hao [1 ]
Liang, Yujie [2 ,4 ]
Xu, Xiao [2 ,5 ]
机构
[1] Jining Med Univ, Affiliated Hosp, Dept Hematol, Jining 272029, Shandong, Peoples R China
[2] Jining Med Univ, Affiliated Hosp, Jining 272029, Shandong, Peoples R China
[3] Chinese Univ Hong Kong, Dept Chem, Shatin, Hong Kong, Peoples R China
[4] Jining Med Univ, Coll Rehabil Med, Jining 272029, Shandong, Peoples R China
[5] Shenzhen Univ, Shenzhen Peoples Hosp 2, Affiliated Hosp 1, Shenzhen 518035, Peoples R China
基金
中国国家自然科学基金;
关键词
CELL MATURATION ANTIGEN; MESENCHYMAL STEM-CELLS; NATURAL-KILLER-CELLS; QUALITY-OF-LIFE; OPEN-LABEL; MONOCLONAL-ANTIBODY; T-CELLS; PHASE-I; PLUS POMALIDOMIDE/DEXAMETHASONE; DARATUMUMAB MONOTHERAPY;
D O I
10.1038/s41420-024-01818-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Multiple myeloma (MM) remains an incurable hematological malignancy disease characterized by the progressive dysfunction of the patient's immune system. In this context, immunotherapy for MM has emerged as a prominent area of research in recent years. Various targeted immunotherapy strategies, such as monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T cells/natural killer (NK) cells, and checkpoint inhibitors have been developed for MM. This review aims to discuss promising experimental and clinical evidence as well as the mechanisms of action underlying these immunotherapies. Specifically, we will explore the design of exosome-based bispecific monoclonal antibodies that offer cell-free immunotherapy options. The treatment landscape for myeloma continues to evolve with the development of numerous emerging immunotherapies. Given their significant advantages in modulating the MM immune environment through immune-targeted therapy, these approaches provide novel perspectives in selecting cutting-edge treatments for MM.
引用
收藏
页数:17
相关论文
共 50 条
[21]   Emerging immune targets for the treatment of multiple myeloma [J].
Sohail, Atif ;
Mushtaq, Adeela ;
Iftikhar, Ahmad ;
Warraich, Zabih ;
Kurtin, Sandra E. ;
Tenneti, Pavan ;
McBride, Ali ;
Anwer, Faiz .
IMMUNOTHERAPY, 2018, 10 (04) :265-282
[22]   Is immunotherapy here to stay in multiple myeloma? [J].
Rodriguez-Otero, Paula ;
Paiva, Bruno ;
Engelhardt, Monika ;
Prosper, Felipe ;
Miguel, Jesus F. San .
HAEMATOLOGICA, 2017, 102 (03) :423-432
[23]   Immunotherapy Strategies Against Multiple Myeloma [J].
Ma, Jing ;
Li, Qian ;
Yu, Zhen ;
Cao, Zeng ;
Liu, Su ;
Chen, Lin ;
Li, Han ;
Gao, Shuang ;
Yan, Tinghui ;
Wang, Yafei ;
Liu, Qiang .
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (06) :717-726
[24]   Immunotherapy of multiple myeloma [J].
Minnie, Simone A. ;
Hill, Geoffrey R. .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) :1565-1575
[25]   Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer [J].
Jafari, Sevda ;
Molavi, Ommoleila ;
Kahroba, Houman ;
Hejazi, Mohammad Saied ;
Maleki-Dizaji, Nasrin ;
Barghi, Siamak ;
Kiaie, Seyed Hossein ;
Jadidi-Niaragh, Farhad .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2020, 77 (19) :3693-3710
[26]   Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma [J].
Varga, Cindy ;
Laubach, Jacob P. ;
Anderson, Kenneth C. ;
Richardson, Paul G. .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (04) :433-446
[27]   Antibody based immunotherapy for multiple myeloma: it's about time [J].
Sher, Taimur ;
Gertz, Morie A. .
LEUKEMIA & LYMPHOMA, 2016, 57 (02) :269-275
[28]   Targeted Therapy With Immunoconjugates for Multiple Myeloma [J].
Bruins, Wassilis S. C. ;
Zweegman, Sonja ;
Mutis, Tuna ;
van de Donk, Niels W. C. J. .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[29]   Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets [J].
Kumar, Ayana R. ;
Devan, Aswathy R. ;
Nair, Bhagyalakshmi ;
Vinod, Balachandran S. ;
Nath, Lekshmi R. .
MOLECULAR BIOLOGY REPORTS, 2021, 48 (12) :8075-8095
[30]   Immunotherapy strategies for multiple myeloma: the present and the future [J].
Locke, Frederick L. ;
Nishihori, Taiga ;
Alsina, Melissa ;
Kharfan-Dabaja, Mohamed A. .
IMMUNOTHERAPY, 2013, 5 (09) :1005-1020